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This study describes the discovery of a new inherited disorder of glycosylation named “CDG-Ik.”CDG-Ik (congenital
disorder of glycoslyation type Ik) is based on a defect of human mannosyltransferase I (MT-I [MIM 605907]), an
enzyme necessary for the elongation of dolichol-linked chitobiose during N-glycan biosynthesis. Mutations in
semiconserved regions in the corresponding gene, HMT-1 (yeast homologue, Alg1), in two patients caused drastically
reduced enzyme activity, leading to a severe disease with death in early infancy. One patient had a homozygous
point mutation (c.773CrT, S258L), whereas the other patient was compound heterozygous for the mutations
c.773CrT and c.1025ArC (E342P). Glycosylation and growth of Alg1-deﬁcient PRY56 yeast cells, showing a
temperature-sensitive phenotype, could be restored by the human wild-type allele, whereas only slight restoration
was observed after transformation with the patients’ alleles.
Introduction
Mannosyltransferase I (MT-I [MIM 605907]) catalyzes
the ﬁrst mannosylation reaction in the biosynthesis of
dolichol-linked oligosaccharides, forming a b1,4-linkage
with the adjacent N-acetylglucosamine (GlcNAc) residue
of chitobiose (Couto et al. 1984). In Saccharomyces cer-
evisiae, the transferase is encoded by asparagine-linked
glycosylation 1 (Alg1). The coding sequence of the hu-
man MT-I gene, HMT-1 (also named “HMAT-1” [hu-
man mannosyltransferase 1]; GenBank accession num-
ber AB019038), was found by homology search by use
of the yeast gene (Takahashi et al. 2000). HMT-1 en-
codes an unglycosylated 52.5-kDa type II transmem-
brane protein consisting of 464 amino acids. Its amino
acid identity to the yeast homologue is 36%. The human
protein was found to complement the growth phenotype
of the yeast ALG1 mutant (Takahashi et al. 2000).
In yeast, the gene defect results in hypoglycosylation
of glycoproteins (Huffaker and Robbins 1982, 1983).
GlcNAc2-PP-dolichol and, to a lesser extent, GlcNAc-PP-
dolichol are accumulated at the restrictive temperature
(36C), but not at the permissive temperature (26C)
(Huffaker and Robbins 1982, 1983). The accumulated
GlcNAc2-PP-dolichol must be able to translocate across
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the membrane of the endoplasmic reticulum (ER), since
it can be transferred to newly synthesized proteins in
ALG1 cells (Cueva et al. 1998). The ALG1 phenotype is
largely corrected by increasing the GDP-mannose pool
by use of overexpression of GDP-mannose synthase
(GDP-mannose pyrophosphorylase, Mpg1p), whereas
the addition of 10 mM mannose to the culture medium
had no effect (Janik et al. 2003).
In this study, we describe a new inherited metabolic
disease, which is caused by a defect of HMT-1. The
disease belongs to the rapidly growing group of dis-
orders affecting glycan biosynthesis named “congenital
disorders of glycosylation” (CDG). According to the
current nomenclature, HMT-1 deﬁciency is named
“CDG-Ik.” The clinical phenotype of the ﬁrst two iden-
tiﬁed patients with CDG-Ik analyzed in this study was
unusually severe, with death in early infancy.
Material and Methods
Patients
Skin biopsies were taken from two patients (NK, GM)
after informed consent of the parents, and ﬁbroblasts
were cultivated in minimal essential medium (MEM).
EDTA blood samples were taken from the parents to
extract genomic DNA to conﬁrm their heterozygous car-
rier status.
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Table 1
Yeast Strains Used in Study
Yeast Type Yeast Strain
Control strains:
AH22 MATa, leu2 his4, Cir/
BY4741 MATa, his3D1 leu2D0 met15D0 ura3D0
Mutant strains:
pRY55 MATa, alg1-1 ura3-52
pRY56 MATa, alg1-1 ura3-52
pRY59 MATa, alg1-1 ura3-52
Yeast Strains
The yeast strains that were used for the experiments
are listed in table 1. (For reference, see the Saccharo-
myces Genome Database Web site.)
Yeast Culture
Yeast cells were grown in YPD medium containing
1% yeast extract, 2% peptone, and 1% glucose (pH
6.5). Selection was done in YNB medium (Difco yeast
nitrogen base [BD Biosciences]) with 2% glucose. Fi-
nally, 2% agar was added for plates.
Labeling of Human Fibroblasts and Yeast Cells
Fibroblasts were labeled for 30 min or 1 h with 100
mCi [2-3H]mannose (speciﬁc activity 10–20 Ci/mmol) or
500 mCi [6-3H]glucosamine (speciﬁc activity 15–35 Ci/
mmol) per ml of Dulbecco’s Modiﬁed Eagle Medium
without glucose (1.2:1) (50 mM mannose) and were
washed with PBS. Yeast cells were labeled for 20 min
with 2 mCi [2-3H]mannose or [6-3H]glucosamine per ml
YP medium (1% yeast extract, 2% peptone [pH 6.5]).
Before labeling, the cells had been grown overnight at
30C in YP medium with 1% glucose. Of this preculture,
10% were used to inoculate the main culture, which
grew for 4 h in log phase until cells were harvested and
labeled.
Extraction of Lipid-Linked Oligosaccharides (LLO) and
Protein-Derived Oligosaccharides (PDO)
For LLO and PDO isolation, cells were extracted three
times with chloroform:methanol (2:1). The pellet was
dried under nitrogen and extracted several times with wa-
ter. Dolichylpyrophosphate-linked oligosaccharides were
predominantly recovered from the subsequent chloro-
form:methanol:water (10:10:3) extract and released by
mild acid hydrolysis for 20 min at 100C in n-propanolol:
0.1 N HCl (1:2). The pellet obtained by the chloroform:
methanol:water extraction was digested overnight at
37C with PNGase F (New England BioLabs) after de-
naturation for 10 min at 100C to release the protein-
linked oliogsaccharides.
For thin-layer chromatography (TLC), dolichol-linked
oligosaccharides were extracted with chloroform:meth-
anol (3:2) and were separated on Silica IB2 plates (Mal-
linckrodt Baker) by use of chloroform:methanol:water
(65:25:4) as solvent. For each lane, ∼300,000 dpm were
transferred to the plate. For the detection of radioactiv-
ity, ﬁlms were exposed for 4 d at 80C to dried TLC
plates treated with EN3HANCE (NEN Life Science
Products). Spots were scraped from the TLC plate and
counted in a scintillation counter.
Mutation Analysis
mRNA was transcribed by reverse transcriptase (1st
Strand cDNA Synthesis Kit [Roche]), and the coding
sequence of the human MT-I was ampliﬁed by PCR.
Primers were HMT-1f 5′-GTACGGATCCGGCGGGC-
CAGCCAAGATGGC-3′ and HMT-1r 5′-GATCGTCG-
ACCAACGTGGACACACTCAGTT-3′ (Takahashi et al.
2000). The samples were incubated at 94C for 3 min.
After 35 cycles of 94C for 1 min, 55C for 45 s, and
72C for 2 min, a ﬁnal incubation was performed at
72C for 10 min. Proof-reading polymerase Pfx (Invi-
trogen) was used for the generation of amplicons for
expression cloning. For sequencing, PCR products were
cloned by TA-cloning and sequenced with standard
primers by use of an automated DNA sequencer (Ap-
plied Biosystems).
Since several pseudogenes for HMT-1 exist in the hu-
man genome, only primers with 3′-ends matching the
correct HMT-1 sequence were selected. For conﬁrmation
of the mutations at the genomic level, exons 7 and 10
were ampliﬁed using the primers HMT-1-Ex7-f 5′-GCC-
ACGGCAGGAGATGCCTC-3′, HMT-1-Ex7r 5′-CAG-
CTCACAGGCCCTCCCG-3′, HMT-1-Ex10-f 5′-ACA-
CACCCCTGCAGGTCTCA-3′ and HMT-1-Ex10-r
5′-ACCCCTTGGTAAACGGCCC-3′. The exon 7 PCR
was incubated at 94C for 3 min, and the samples were
cycled 35 times: 94C for 1 min, 60C for 45 s, and 72C
for 1 min. Final incubation was at 72C for 10 min. The
same conditions were used for the exon 10 PCR, with
an annealing temperature of 62C and the addition of
Q-Solution (Qiagen) for the incubations.
To exclude common polymorphisms, 100 alleles of
healthy donors of white European background were se-
quenced in each case. In this investigation, the published
sequences of human HMT-1 at the genomic level
(GenBank accession numberNT_010552) and of the cod-
ing region (GenBank accession numbers AB019038 and
NM_019109) have been used and conﬁrmed.
Mannosyltransferase Assays
The reactions contained the following in a ﬁnal vol-
ume of 0.06 ml: [14C]GlcNAc2-PP-dolichol (4,000 cpm)
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Figure 1 IEF of serum transferrin. The numbers on the right
describe the numbers of sialic acids. Transferrin has two branched
carbohydrate side chains, each bearing two sialic acids at the end.
Fully glycosylated transferrin has four sialic acids; higher branching
leads to increased numbers of sialic acids in a small fraction of the
protein. Patients with CDG-Ia have either one or both carbohydrate
side chains missing in about half of the transferrin population. The
hypoglycosylation in CDG-Ik is much more severe.
or Man1[
14C]GlcNAc2-PP-dolichol (4,000 cpm), 0.13%
Nonidet P40, 10 mM MgCl2, 0.9 mM DTT, 0.14 mM
Na-EDTA, 19 mM Tris-HCl (pH 7.2), 1 mM GDP-Man
and solubilized enzyme (equivalent to 50 mg membrane
protein). Incubations were performed at 37C for the
durations indicated. Reactions were stopped by addition
of chloroform:methanol to give a ratio of chloroform:
methanol:water of 2:1:1 (by vol) and were processed
further by phase separation (Sharma et al. 1982) by use
of an upper phase of chloroform:methanol:water of 1:
32:48 (by vol) and by collecting both lower phase and
interphase. The solubilized extract was obtained from a
particulate ﬁbroblast fraction prepared as described else-
where (Knauer and Lehle 1994; Thiel et al. 2002), except
that membranes were suspended in 20 mM Tris (pH
7.2), 10 mM MgCl2, and 1 mM DTT. Solubilization was
performed at a protein concentration of 7 mg/ml and
1% Nonidet P40. Preparation of [14C]GlcNAc2-PP-dol-
ichol and Man1[
14C]GlcNAc2-PP-dolichol acceptors was
performed using as enzyme source a solubilized extract
from yeast membranes, as described elsewhere (Thiel et
al. 2003).
Construction of the Expression Vector
The cDNA generated by the PCR reaction by use of
HMT-1f and HMT-1r (described above) was digested
with BamHI and SalI (New England BioLabs) and cloned
into the expression vector pYEX-BX (Clontech) that had
been digested with the same enzymes. After ampliﬁcation
in bacteria (TOP10F′ (Invitrogen]), the vector constructs
were puriﬁed and the sequence of the coding region was
veriﬁed by sequencing by use of an automated DNA se-
quencer and standard procedures (Applied Biosystems).
Induction of the yeast expression from pYEX-BX was
done by the addition of 0.4 mM CuSO4 to the culture
medium. Transformation was done using standard pro-
cedures (Gietz and Woods 2002).
Results
Patients
Two patients (NK, GM) with a defect of b1,4-man-
nosyltransferasewere identiﬁed and analyzed in this study.
Both patients had a type I isoelectric focusing (IEF)pattern
of serum transferrin with a hypoglycosylation muchmore
pronounced than that found in the most common CDG,
CDG-Ia (ﬁg. 1). In early infancy, the children presented
with recurrent seizures refractory to anticonvulsive ther-
apy, rapidly developing microcephaly, and severe coag-
ulation abnormalities. Patient NK was incapable of visual
ﬁxation. Seizures started at 5 mo of age. General cerebral
atrophy was revealed by MRI. Frequent episodes of un-
explained fever occurred. The boy developed progressive
stupor and died at 10 mo of age. Patient GM developed
seizures already 2 h after birth. At 1 mo of age, severe
muscular hypotonia was present and MRI revealed ce-
rebral atrophy. Nephrotic syndrome was present and a
severe decrease of circulating B-cells with a complete ab-
sence of immunoglobulin G (IgG) in the blood was no-
ticed. Severe seizures and progressive stupor developed,
and the boy died from respiratory failure at 11 wk of age.
More details about the clinical phenotype and the hy-
poglycosylation of serum glycoproteins in this disorder
will be described elsewhere (Marquardt et al., unpub-
lished data).
Metabolic Labeling of Fibroblasts
Subconﬂuent ﬁbroblasts of the two patients were la-
beled with 100 mCi [2-3H]mannose and 10 mCi [35S]me-
thionine per ml for 30 min, as described elsewhere
(Kranz et al. 2001). LLO were subjected to high-per-
formance liquid chromatography (HPLC) analysis and
showed a major oligosaccharide peak at the position of
Glc3Man9GlcNAc2, indicating that LLO after mannose
labeling were structurally intact (not shown). To deter-
mine the amount of newly synthesized LLO, the radio-
activity incorporated into LLO was determined and
related to the amount of total cellular protein. On aver-
age, the amount of radioactivity incorporated after
[2-3H]mannose labeling into newly synthesized LLOwas
reduced to 29.1% in patient NK and to 39.9% in patient
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Figure 2 TLC of dolichol-linked oligosaccharides. Fibroblasts
were labeled with [3H]glucosamine for 1 h, and dolichol-linked oli-
gosaccharides were extracted with chloroform:methanol (3:2), as de-
scribed. Lanes 1–3 show ﬁbroblasts (GM, NKp CDG-Ik ﬁbroblasts;
cp control ﬁbroblasts). Lanes 4–5 show yeast ﬁbroblasts (wtp wild
type; PRY56 p ALG1 mutant). 1 p migration of higher–molecular-
weight dolichol-linked oligosaccharides, 2pmigration of the dolichol-
linked oligosaccharides accumulated in the ALG1 mutant.
Table 2
Mannose and Glucosamine Incorporation
SUBJECT
RADIOACTIVITY (%)
INCORPORATED INTO LLO
AFTER LABELING WITH
[3H]mannose [3H]glucosamine
Control 100 100
Patient NK 29.1 (n p 5) 185.0 (n p 3)
Patient GM 39.9 (n p 4) 119.6 (n p 3)
NOTE.—Fibroblasts were labeled for 30 min
with 100 mCi [2-3H]mannose or [6-3H]glucos-
amine per ml labeling medium and dolichol-
linked oligosaccharides were extracted as de-
scribed. Total cellular protein amount was
determined, and the ratio of the incorporated la-
bel to the total cellular protein was calculated.
Controls were set to 100.
GM (table 2). Labeling with [3H]glucosamine revealed
an increased incorporation (table 2). The results dem-
onstrated that the patients’ cells synthesized a reduced
amount of mature LLO and that glucosamine incor-
poration was not diminished, whereas mannose incor-
poration was greatly reduced. Since no truncated oli-
gosaccharides were observed in the HPLC analysis of
mannose-labeled LLO, we concluded hat the cells must
have an early defect in the incorporation of mannose
into LLO, most likely in the incorporation of the ﬁrst
mannose.
Accumulation of GlcNAc2-PP-Dolichol in Fibroblasts
Fibroblasts were labeled with 500 mCi/ml [3H]glucos-
amine for 1 h and LLO were extracted. Next, 300,000
dpm of the labeled sample was placed on a TLC plate
and separated, as described above. Wild-type and ALG1
yeast were labeled at the same time as controls. Three
different ALG1 mutants (PRY55, PRY56, and PRY59),
known to produce mainly GlcNAc2-PP-dolichol (Huf-
faker and Robbins 1982, 1983), accumulated the radio-
active label in a band migrating further than in the two
different wild-type yeast strains (ﬁg. 2, row 2). Thus, dol-
ichol-linked oligosaccharides extracted from labeled
ALG1 yeast cells were used as controls. This band was
not found after labeling with [3H]mannose, demonstrat-
ing that the band contained only glucosamine and no
mannose (not shown).
The radioactive label in control ﬁbroblasts wasmainly
found in higher–molecular-weight dolichol-linked oli-
gosaccharides, as demonstrated by HPLC. These doli-
chol-linked oligosaccharides migrated on TLC plates to
the same position as the one isolated from wild-type
yeast cells. CDG-Ik ﬁbroblasts also synthesized higher–
molecular-weight oligosaccharides, as found in their
wild-type counterparts, but, in addition, they showed an
accumulation at the position of the band with higher
mobility found in ALG1 yeast known to accumulate
GlcNAc2-PP-dolichol. Quantiﬁcation of the bands by
scintillation counting revealed that both CDG-Ik ﬁbro-
blast cultures accumulated approximately three times
more label at the GlcNAc2-PP-dolichol position than
healthy controls. In contrast to ALG1 yeast cells, the
majority of the label in CDG-Ik cells was recovered at
the wild-type position, indicating that the defect must
be leaky in the two patients.
Elongation of GlcNAc2-PP-Dolichol in the Presence of
Cell Extracts
The substrate for the MT-I reaction, [14C]-labeled
GlcNAc2-PP-dolichol, was incubated in the presence of
detergent-solubilized membrane extracts from control
and patient ﬁbroblasts. Incubations were done for 12
min in the presence of 1 mM GDP-mannose. The re-
actions were stopped by the addition of chloroform:
methanol, and dolichol-linked oligosaccharides were an-
alyzed by HPLC.
In control extracts, nearly half of the substrate was
elongated, mainly to Man5GlcNAc2-PP-dolichol (ﬁg.
3A). In ﬁbroblast extracts from both patients, only a
small fraction of the substrate was elongated (about
10% of controls), conﬁrming the deﬁciency of the elon-
gation reaction for the GlcNAc2 substrate.
To demonstrate that the subsequent mannosylation re-
action was unaffected, Man1[
14C]GlcNAc2-PP-dolichol
was used as substrate in the presence of GDP-mannose
(ﬁg. 3B). In the control, the substrate (ﬁg. 3B.a) was elon-
gated after 4 min incubation to Man3–5[
14C]GlcNAc2-PP-
dolichol (ﬁg. 3B.b). In both patients with CDG-Ik, the
elongation that occurred was the same as in the control
(ﬁg. 3B.c and 3B.d), demonstrating a speciﬁc deﬁciency
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Figure 3 In vitro elongation of GlcNAc2-PP-dolichol (A) or Man1GlcNAc2-PP-dolichol (B). NK and GM are patients with CDG-Ik. [14C]-
labeled GlcNAc2-PP-dolichol was incubated in the presence of detergent-solubilized membrane extracts from control and patient ﬁbroblasts.
Dolichol-linked oligosaccharides were analyzed by HPLC. In control extracts, nearly half of the substrate A). To demonstrate that the subsequent
mannosylation reaction was unaffected, Man1[
14C]GlcNAc2-PP-dolichol was used as substrate (B). In both patients with CDG-Ik (B.c, B.d),
elongation occurred equal to that in the control (B.a, B.b). GN p N-acetylglucosamine; M p mannose.
in the ﬁrst mannosylation reaction and unaffected sub-
sequent biosynthesis steps.
Analysis of the HMT-I Gene
In the ﬁrst patient (NK), mutation analysis of theHMT-
1 gene revealed compound heterozygosity for mutations
c.773CrT (Ser258Leu [paternal]) and c.1025ArC
(Glu342Pro [maternal]). Mutation analysis of the HMT-
1 gene of the second patient (GM) revealed homozygosity
for the mutation c.773CrT (Ser258Leu). These muta-
tions, as well as the heterozygous carrier status of the
parents of both patients, were conﬁrmed at the genomic
level by direct sequencing. Both amino acid substitutions
occurred at semiconserved positions in the protein.
Growth Phenotype of Transformed ALG1 Yeast
It has been shown that ALG1 yeast cells can be com-
plemented by transformation with the human MT-I cod-
ing sequence (Takahashi et al. 2000). Since the human
ALG1 homologue can complement the deﬁcient yeast
gene, yeast cells can serve as a model system to study
the functional consequences of the mutations found in
the two patients. S. cerevisiae PRY56 cells were trans-
formed with an expression vector containing either the
wild-type coding region of HMT-1 or one of the mutated
alleles. Mock transfection was done with the vector car-
rying no insert. Transformed uracil auxotroph cells were
selected by growth on YNB plates containing no uracil.
After the selection, cells were placed in sequential 10-
fold dilutions on YPD plates. PRY56 cells have a tem-
perature-dependent phenotype (Huffaker and Robbins
1982). At the permissive temperature of 26C, cells
transformed with the mutated alleles had growth com-
parable to wild-type or mock-transformed cells (ﬁg. 4,
left panel). At the restrictive temperature of 36C, the
mock-transformed ALG1-deﬁcient cells showed de-
creased growth compared with wild-type transformed
cells (ﬁg. 4, right panel). Cells transformed with either
the 1025ArC allele or the 773CrT allele showed a par-
tial restoration of the wild-type phenotype but still had
decreased growth when compared with the wild-type
transformed cells. Neither of the two mutations was able
to restore normal growth in PRY56 cells, demonstrating
an impaired function of the corresponding alleles. The
same phenotype was found by analysis of LLO (not
shown) and of carboxypeptidase Y (CPY) glycosylation
(see online-only appendix A).
Discussion
CDG-Ik is caused by a defect in the ﬁrst mannosylation
reaction of N-glycan biosynthesis. Compared with other
CDG types, the phenotype is very severe, with rapid
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Figure 4 Growth characteristics of transformed PRY56 yeast cells showing 10-fold dilutions from top to bottom. Pictures were taken
after 1 wk at the permissive temperature (26C, left) or at the restrictive temperature (36C, right). From left to right, wild-type transformed
cells, transformed cells with the 1025ArC (NK) allele, transformed cells with the 773CrT allele (both patients), and mock-transformed cells.
development of microcephaly, seizures refractory to
treatment, progressive stupor, and death in early infancy.
The hypoglycosylation of liver-derived serum glyco-
proteins was more profound than in CDG-Ia. Metabolic
labeling of the cells with 2-[3H]D-mannose, the standard
procedure for the investigation of CDG ﬁbroblasts, re-
vealed a total amount of newly synthesized dolichol-
linked oligosaccharides that was reduced to 30%–40%
of that of control cells. HPLC analysis of LLO, as well
as TLC of dolichol-linked oligosaccharides after radio-
active labeling, demonstrated that the patients’ ﬁbro-
blasts were still able to synthesize full-length dolichol-
linked glycans. However, the cells accumulated approx-
imately three times more truncated LLO compared with
control cell lines. The defect of the ﬁrst mannosylation
step was conﬁrmed by an enzyme assay measuring the
ability to elongate GlcNAc2-PP-dolichol, the substrate
of MT-I, that clearly demonstrated a profound reduc-
tion of the elongation ability. The subsequent manno-
sylation steps were unaffected.
Overexpression of the mutated alleles in ALG1 yeast
demonstrated an accumulation of GlcNAc2-PP-doli-
chol, whereas wild-type transformed cells were phe-
notypically corrected. A residual activity of about 10%
in CDG-Ik ﬁbroblasts, as well as the partial restoration
of the LLO and glycosylation phenotypes in ALG1
yeast, imply a relevant residual activity of the mutated
enzyme. The residual activity correlates very well with
the missense mutations in semiconserved regions of the
gene. It has to be assumed that a more profound deﬁ-
ciency of the enzyme will be lethal in humans, maybe
even during intrauterine life, since, even in less complex
cellular systems like yeast cells, a total Alg1 disruption
leads to inviability. For other CDG, it has been shown
that a complete loss of enzymatic activity is incompat-
ible with life (Matthijs et al. 1998).
CDG-Ik is the 15th metabolic defect in N-glycan bi-
osynthesis discovered in the 8 years since the ﬁrst dis-
order was described (van Schaftingen and Jaeken 1995).
Because of the complexity of N- and O-glycan biosyn-
thesis and processing, more CDG will be discovered in
the years to come, making CDG one of themajor groups
of inherited metabolic disorders. CDG are a new chal-
lenge for basic researchers, as well as for physicians; it
is more demanding than ever to use the understanding
of the molecular bases of the diseases to develop effec-
tive treatments for them as has been done so far only
for CDG-Ib and CDG-IIc (Niehues et al. 1998; Mar-
quardt et al. 1999; Lu¨hn et al. 2001).
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